Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets ...
Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...
When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1 ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda. Agilent Technologies Inc. announced that the U.S. Food and ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Consistently, first-line trials of immune checkpoint inhibitors in combination with chemotherapy have demonstrated overall survival benefit for patients with metastatic gastroesophageal cancer.
Experts discuss the importance of PD-L1 testing in treatment decisions for gastric cancer, emphasizing personalized approaches and improved patient outcomes. This segment explores how biomarker ...